VG161
- Generic Name
- VG161
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Oncolytic Virus Therapy Market Size Clinical Trials Sales Forecast 2030
The global oncolytic virus immunotherapy market, projected to exceed USD 1.50 billion by 2030, is advancing with over 180 therapies in clinical trials. Key therapies like IMLYGIC, Oncorine, and Delytact are approved, with more expected due to FDA and EMA designations. Innovations and partnerships, such as RenovoRx and Imugene's collaboration, are driving growth, aiming for safer, targeted cancer treatments.
The next generation of herpes simplex virus-based oncolytic immunotherapy
The article reviews the evolution of oncolytic immunotherapy (OI) since the FDA approved talimogene laherparepvec for melanoma in 2015. It discusses the development of next-generation herpes simplex virus-based OIs, focusing on genetic modifications for safety, tumor-selective replication, and immune stimulation. The review also covers clinical evidence supporting OIs in overcoming resistance to immune checkpoint blockade and explores combination therapies to enhance OI efficacy.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath